Gilead drug fails to confirm its FDA approval in bladder cancer - Silicon Valley Business Journal

Published on 31 May 2024 on The Business Journals

A drug at the center of a $21 billion acquisition by Gilead Sciences Inc. four years ago failed a...

Read the rest of the article

Start tracking your investments with Statfolio

Global drug shortages underscore the pharmaceutical industry's reliance on fragile supply chains,...

Forbes 22 Oct 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new...

Benzinga · via Yahoo Finance 21 Oct 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The...

Insider Monkey · via Yahoo Finance 19 Oct 2024

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in...

Reuters 18 Oct 2024

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S....

Benzinga · via Yahoo Finance 18 Oct 2024

We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 2...

Insider Monkey · via Yahoo Finance 8 Oct 2024

, opens new tab Trodelvy failed to improve survival for patients with advanced bladder cancer and...

Reuters 31 May 2024

A drug at the center of a $21 billion acquisition by Gilead Sciences Inc. four years ago failed a...

The Business Journals 31 May 2024

On Thursday, Gilead Sciences Inc GILD announced topline results from the confirmatory Phase 3 TRO...

Benzinga 31 May 2024

Gilead Sciences, Inc. GILD announced the failure of its late-stage confirmatory TROPiCS-04 study ...

Zacks via Yahoo Finance 31 May 2024